#41 – We (Still) Hope Michael Pollan Changes His Mind
The crew reviews Michael Pollan’s recent New York Times Op-Ed "How Should We Do Drugs Now?”
Top Stories
COMPASS Pathways Is Trying to Patent Psilocybin for More Mental Health Conditions Than You Can Name
by Russell Hausfeld and David Nickles
News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.
The Third Wave’s Paul Austin Has Been Accused of Stealing Information For His Psychedelic Provider Directory
The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.
#41 – We (Still) Hope Michael Pollan Changes His Mind
The crew reviews Michael Pollan’s recent New York Times Op-Ed "How Should We Do Drugs Now?”
#41 – We (Still) Hope Michael Pollan Changes His Mind
The crew reviews Michael Pollan’s recent New York Times Op-Ed "How Should We Do Drugs Now?”
#40 – Part Two: Has Atai Taken the Psychedelic Throne from MAPS? (The Murderous Dictator Episode)
In Part Two Normie, Dave, Russell, and Sarvesh continue their conversation about Atai Life Sciences and how the introduction of for-profit psychedelic pharmaceutical corporations have shifted capital away from non-profits. This episode gets extra wacky and dark as they dive into Atai Founder & Chairman Christian Angermayer's role on Rwandan president Paul Kagame's Advisory Council.
#39 – Part One: Has Atai Life Sciences Taken the Psychedelic Throne From MAPS?
Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences' recent IPO on Nasdaq. They also discuss and provide updates on Russell's previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits.
#38 – Part Two: The Psychedelic Capitalism Debate That Wasn’t
In Part Two, the Psymposia crew continues to deconstruct a conversation between two self-described entrepreneurs who recently discussed psychedelics and medicalization during an event called Psychedelic Capitalism with Alexander Beiner [Rebel Wisdom] and Lars Wilde [COMPASS Pathways, Atai Life Sciences]— while studiously avoiding a debate of capitalism altogether.
Top Stories
The Third Wave’s Paul Austin Has Been Accused of Stealing Information For His Psychedelic Provider Directory
The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.
COMPASS Pathways Is Trying to Patent Psilocybin for More Mental Health Conditions Than You Can Name
by Russell Hausfeld and David Nickles
News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.
Become a member.
Support Us On Patreon.
Livestream – November 19, 2020
We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.
Chemical Poetics: Rebel Wisdom and the Psychedelic IDW
Neşe Devenot, PhD of Psymposia’s Plus Three podcast ventures into the psychedelic “arm” of the Intellectual Dark Web in this first episode of Chemical Poetics.
Series
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
A six part series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Critical Takes
Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19
Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.
Dear Psychedelic Researchers
The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.
Lucy In The Sky With Nazis: Psychedelics and the Right Wing
Psychedelic advocates have long asserted that broader psychedelic use will lead to a more open, progressive society, but there are too many instances of right-wingers who have taken them for that to be true.
Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism
As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”
From Mining to Mushrooms
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Livestream – November 19, 2020
We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.
The LSD Silo Bust according to William Leonard Pickard
Neşe Devenot shares William Leonard Pickard's description of his side of the Silo bust in "The Rose of Paracelsus."
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Critical Takes
Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19
Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.
Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism
As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”
Dear Psychedelic Researchers
The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.
Lucy In The Sky With Nazis: Psychedelics and the Right Wing
Psychedelic advocates have long asserted that broader psychedelic use will lead to a more open, progressive society, but there are too many instances of right-wingers who have taken them for that to be true.
